Connect Portal

  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
  • About
    • About
    • Leadership
    • News
    • Careers
    • Forms
    • Contact

OmniSeq is excited to announce it is now part of Labcorp!

by Christina Black | Jul 29, 2021 | News

Inflammation Signature May Predict Checkpoint Inhibitor Response in Gastroesophageal Cancer, Study Finds

by Christina Black | Jul 22, 2021 | News

Labcorp and OmniSeq Launch Insight, Next-Generation Sequencing Platform to Advance Precision Oncology

by Christina Black | Jun 10, 2021 | News

OmniSeq Receives New York State Approval for Cancer Genomic, Immune Profiling Test

by Christina Black | Apr 27, 2021 | News

Cancer-testis antigen detection by targeted RNA sequencing

by OmniSeq Staff | Dec 3, 2020 | News

Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors.  This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...

Cancer testis antigen co-expression landscape in solid tumors

by OmniSeq Staff | Dec 3, 2020 | News

Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...
« Older Entries

Follow Us on Twitter

Twitter feed is not available at the moment.

  • Facebook
  • Twitter
©2023 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .